Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/8/2018
SIETES contiene 92469 citas

 
 
 1 a 20 de 205 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G. Cerebrovascular outcomes with proton pump inhibitors and thienopyridines. Stroke 2018;49:febrero. [Ref.ID 102619]
2.Enlace a cita original Cita con resumen
Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ 2018;360:6 de febrero. [Ref.ID 102541]
3. Cita con resumen
Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, Southworth MR, Zhang R, Izem R, Goulding MR, Houstoun M, Mott K, Sung SH, Gagne JJ. Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice: a retrospective cohort study. Ann Intern Med 2017;167:845-54. [Ref.ID 102196]
4. Cita con resumen
Quinn KL, Macdonald EM, Mamdani MM, Diong C, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN). Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study. Drug Saf 2017;40:887-93. [Ref.ID 102077]
5. Cita con resumen
Raccah BH, Perlman AI, Danenberg HD, Pollak A, Muszkat M, Matok I. Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure. Chest 2016;149:1516-24. [Ref.ID 101481]
7.Enlace a cita original Cita con resumen
Wändell P, Carlsson AX, Holzmann M, Ärnlöv J, Johansson SE, Sundquist J, Sundquist K. Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation - A cohort study in primary care. Eur J Clin Pharmacol 2017;73:febrero. [Ref.ID 101404]
8.Tiene citas relacionadas Cita con resumen
O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016;388:761-75. [Ref.ID 100609]
9. Cita con resumen
Baharoglu M, Cordonnier C, Salman RAS, de Gans K, Koopman MM, Brand A, Majoie CB, Beenen LF, Marquering HA, Vermeulen M, Nederkoorn PJ, de Haan RJ, Roos YB, PATCH Investigators. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016;387:2605-13. [Ref.ID 100468]
10.Enlace a cita original Cita con resumen
Focks JJ, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheught FWA. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ 2016;353:i2868. [Ref.ID 100461]
11. Cita con resumen
Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 2016;133:1540-7. [Ref.ID 100280]
12. Cita con resumen
Anónimo. Injections épidurales de corticoïde: troubles neurologiques graves. Prescrire 2015;35:429. [Ref.ID 99427]
14. Cita con resumen
The AVERT Trial Collaboration group. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet 2015;386:46-55. [Ref.ID 99330]
15. Cita con resumen
Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385:2288-895. [Ref.ID 99285]
16.Tiene citas relacionadas Cita con resumen
Shin J-Y, Park M-J, Lee SH, Choi S-H, Kim M-H, Choi N-K, Lee J, Park B-J. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ 2015;351:h3517. [Ref.ID 99249]
17.Tiene citas relacionadas Cita con resumen
Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M, Yokoyama K, Ishizuka N. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014;312:2510-20. [Ref.ID 98429]
18.Tiene citas relacionadas
Gaziano JM, Greenland P. When should aspirin be used for prevention of cardiovascular events?. JAMA 2014;312:2503-4. [Ref.ID 98428]
19. Cita con resumen
20. Cita con resumen
Anónimo. Treatment of atrial fibrillation. Med Lett Drugs Ther 2014;56:53-8. [Ref.ID 97926]
Seleccionar todas
 
 1 a 20 de 205 siguiente >>